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In this thesis we would like to assess the benefit of screening in breast cancer
detection. For this purpose, the Health Insurance Plan data will be analyzed.
If screening is beneficial, we expect to see higher early stage detection in the
study group compare to the control group which hopefully will lead to a better
survival probability.
Our analysis shows that there is a significantly higher combined stage I de-
tection proportion in the study group compared to the control group (50.00%
in the control group as opposed to 67.77% in the study group). Furthermore,
the study group has a significantly lower proportion of breast cancer deaths than
the control group. The Kaplan-Meier estimate shows that the study group has a
better survival function than the control group. In addition to these, we shows
that there exists no significant lead time. Lastly, we construct a Markov chain
model for future analysis.
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Assessing the efficacy of screening for cancer is an outstanding problem in cancer
research. The problem has been studied by medical researchers around the world.
In a screening trial for breast cancer the participating women are divided into a
study group and a control group according to a certain randomization procedure.
Women in the study group will be offered a number of screening examinations
for breast cancer over a period of time while women in the control group will
not be invited for any screening. The participants in both groups are followed
up for a long period of time, years beyond the screening period, to record their
incidence and mortality of breast cancer. The principal question addressed in the
assessment of the efficacy of screening is “Would the screening decrease breast
cancer mortality?”
The majority of the published reports found that screening for the breast
cancer is beneficial for women. For instance, by analyzing the data from the
Health Insurance Plan of Greater New York (HIP) collected during the 1960’s.
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Shapiro et al. (1982) concluded that by the end of 10 years after entry to screening
study, breast cancer mortality was about 30% less in the study group than that
in the control group. In another paper, Shapiro (1997) found that by the end
of 18 years since entry to the study, the study group has about a 25% lower
breast cancer mortality among women aged 40-49 and 50-59 (at time of entry)
than that in the control group. Analyzing the same HIP data using a competing
risks model, Aron and Prorok (1986) found that some but not all of the breast
cancer cases detected early by screening realized a benefit in terms of reducing
the breast cancer mortality. But screening appears not to affect the mortality
rate from causes of death other than breast cancer.
Based on the NHS screening program conducted in England and Wales, Blanks
et al. (2000) concluded that the total reduction of the breast cancer mortality
for the study group was estimated as 21.3%.
Yet, there were researchers who reported that screening was not beneficial for
women. Gotzsche et al. (2000) concluded that screening for breast cancer with
mammography is unjustified. They reviewed each of the eight such screening
trials that they could find in the public domain at the time, including the HIP
study, and found that in six of the eight, the randomization process failed to
create a study group similar to the control group, and that the remaining two
trials, although adequately randomized were did not prove the effectiveness of
screening.
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Comparison between the study group and the control group is a very difficult
task. Dividing individuals into a study group and a control group by randomiza-
tion is conceptually simple but hard to carry out. Selection bias (not necessarily
done knowingly) and noncompliance of the participants often pose serious prob-
lems for performing randomization. In the case of the HIP study, the question
of why twice as many women in the study group as in the controlled group were
excluded from participation due to their pre-existing breast cancer condition is
still not resolved. If the screening trial were truly random, one would expect
about the same number excluded from each group. The imbalance suggests that
some sort of selection bias was there. It was also known in the HIP screening trial
that a significant number of women refused to be screened at all while others who
were willing but failed to show up for a scheduled screening. The noncompliance
will not only affect randomization but also reduce the potential effectiveness of
screening. These problems cast doubts on the comparability of the study group
with the control group.
In addition to the randomization problems, the selection of the outcome vari-
ables (or endpoints), cohorts, and statistical methods for analysis also contributed
to the conflicting research results. For example, some researchers measured a pa-
tient’s survival time from the date of entry to the time of death, while others
used the time of diagnosis as the initial time. Another major reason for different
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findings is due to the selection of time period for comparing survival or mortality
of the breast cancer patients.
Lastly, the heterogeneity of the patients makes the data analysis difficult.
One could reduce the heterogeneity by limiting the investigation to a specific age-
demographic cohort, but then sample size would become too small for analysis.
In this thesis we study the efficacy of screening using the HIP data with special
attention to the non-compliance problem, the selection of cohorts for comparing
the study group and the control group, and the selection of outcome variables.
The endpoint results collected by HIP are trivariate. It consists of death
from breast cancer, death from other causes and survival of breast cancer of all
those cancer cases detected during the entire period of the screening trial. If
the endpoint results were bivariate with only the death from breast cancer and
the survival of breast cancer, then the comparison using the breast cancer death
proportions would be straight forward. In the trivariate situation, the question
of “How do we use the information on death from other causes” needs to be
carefully addressed.
In Shapiro et al. (1982), the breast cancer mortality was computed in two
different ways, either (a) using only the breast cancer deaths and separately
considering the mortality from other causes or (b) including the deaths from
other causes into the category of deaths from breast cancer. On the contrary,
we believe that the death from other causes should be considered as “censored”
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survival times and hence to be included in the category of “survival of the breast
cancer”. Excluding or including the category of “death from other causes” as in
approaches (a) and (b) would bias the calculation of the breast cancer mortality.
If screening is beneficial, one would expect a higher curing percentage of the
breast cancer in the screening group than that of the control group. (We should
note that curing means the cancer is in remission.) Therefore, by the end of the
follow-up period, the screening group would have a lower proportion of breast
cancer deaths and a higher proportion of deaths from other causes than that of
the control group. Indeed this problem was investigated by Aron and Prorok
(1986). However, our study differs from that of Aron and Prorok (1986) in the
selection of cohort and the time period for comparison.
In this thesis we consider the trivariate outcome variables of the breast cancer
patients detected in the study group and in the control group over the same
period of 54 months (4.5 years) since the entry date of each participant. Four
and half years is chosen to include the last screened-detected cancer case in the
study group measured from her date of entry to the program. Our rationale is
that after the cessation of screening (in 4.5 years), there were no more screening
detected cancer cases in the study group. Therefore, the effect of screening should
be investigated only during this period. Thus we do not include cancer cases
detected in the ensuing follow-up period in the comparison. This is another
difference between our investigation and that of the others. See, for example
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Shapiro et al. (1982), Aron and Prorok (1986), Chu (1988) and Shapiro (1997).
In the literature, cancer cases detected in various time periods, such as 5, 6, 7
and 10 years after the entry date have been used for comparing the study group
and the control group. Some researchers chose a longer time period because
of concern about false-negative screening results in the study group during the
screening period and thus extended the time period for cancer detection to make
allowance for “under detection” in the study group due to false negative result.
However, lack of definitive conclusion about false negative result, this becomes a
subjective choice.
We also have investigated five-year survival probability in this thesis. The
five-year survival probability is the proportion of women alive five years after
they were diagnosed with breast cancer.
A host of other issues arise in the analysis of the screening data. Among them
we have addressed the problem of lead time.
The thesis is organized as follows. In Chapter 2, we give detailed descriptions
of the HIP study. In Chapter 3, hypothesis testing is performed to test the
equality of death proportions and survival proportions in the study group, control
group and refused group. Next in Chapter 4, statistical tests concerning the
difference in life expectancy among three groups were conducted. In Chapter 5,
analysis of detection in early stages was conducted. Chapter 6 contains analysis of
five-year survival probability. Analysis of the lead time is conducted in Chapter 7.
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In Chapter 8, we propose a Markov chain for a future study and investigate what
kind of data and sample size would be needed in future screening trials. The
concluding remarks are given in Chapter 9.
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Chapter 2
The HIP Randomized Controlled Trial and Selection of
Cohorts
The Health Insurance Plan (HIP) study was initiated in December 1963 in the
state of New York. The primary objective of the HIP study was to determine
if periodic screening for breast cancer with mammography and clinical breast
examination is beneficial for women.
In the beginning of the study, 62,000 women between ages 40 and 64 years
with at least one year membership in HIP were randomly assigned to the study
group and the control group. The randomization was performed in such a way
that every other women in the data base was assigned to the control group which
split the total number into two equal groups with 31,000 women in each group.
However, 869 women in the study group and 435 women in the control group
were excluded from the trial because those women were identified as having a
prior breast cancer diagnosis. This left the HIP study with 30,131 women in the
control group and 30,565 women in the study group. Each woman in the study
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group was offered an initial screening for the breast cancer and three annual
screening afterwards. However, 9,984 women assigned to the study group refused
to participate in the screening. This reduced the sample size of the study group
to 20,147 women. Those women who refused screening were also followed up
and their data will be analyzed separately. The reason for conducting a separate
analysis on the refused group is that it has been well established in the literature
that women in the refused group have different characteristics. Thus the break




The follow-up of the entire control group, the study group and the refused
group for breast cancer incidence and general mortality were conducted in the
form of mail surveys 5, 10 and 15 years after after entry date for each woman.
There were several women lost to follow-up, but fortunately the subset data used
in this thesis does not have any woman lost to follow-up.
2.1 Screening and Cancer Detection
As mentioned above, women in the study group were offered an initial breast can-
cer screening examination and three subsequent annual breast cancer screening
examinations.
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Each examination consisted of a film mammography (cephalocaudal and lat-
eral views of each breast), a clinical examination of the breast by a physician
(usually a surgeon) and an interview for demographic and other background
information. The mammography and the clinical examination were done sepa-
rately/independently and later the findings were coordinated for reports to the
women and their personal physician.
In addition to these four screening examinations, if the screening examination
of a woman showed a questionable result, there could be a strong indication of
cancer but not sufficient evidence to declare cancer, that particular woman would
be recalled for early screening examination.
For women who were diagnosed with the breast cancer, the following data
were collected with regard to when the breast cancer was diagnosed and whether
it was attributed to screening.
1. Initial screening
2. Initial screening on early recall
3. First annual screening
4. First annual screening on early recall
5. Second annual screening
6. Second annual screening on early recall
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7. Third annual screening
8. Third annual screening on early recall
9. Last exam was initial
10. Last exam was first annual
11. Last exam was second annual
12. Last exam was third annual
13. No histologic confirmation prior to death
Detection types from item 1 to 8 were attributed to the breast cancer screening
examination, but not types 9 to 13. Types 9-13 mean that the breast cancer was
detected between screenings and they are called interval detected cancer cases.
Interval detection may occur due to a variety of reasons, including cancer was
too small to be detected at the time of screening, false-negative result at one or
more previous screenings, noncompliance by the participants, such as missing a
scheduled screening or not following a recommendation for a biopsy/aspiration
given after an examination, or simply dropping out the study. The issue of
noncompliance will be discussed in Section 2.4.
Because the focus of this thesis is to access the efficacy of breast cancer screen-
ing, ideally we would like to use cases that were attributed to screening only.
However, the issue of noncompliance make the task of separating cases that were
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attributed to screening and cases that were not attributed to screening very dif-
ficult. Thus we decide to use all cancer cases.
Information from different sources was used to identify cause of death in all
three groups. These sources included HIP records, hospital claim files, death
records in several states, cancer registry for New York State, the National Death
Index and the mail surveys. Cause of death was determined by reviewing death
certificates and hospital and physicians’ records. The reviewers were blinded to
which group were the women in.
2.2 Selection of Cohorts for Comparison
The reason for conducting a screening trial is to assess whether periodical screen-
ing lead to detection of cancer at its early stages of growth, thereby increasing
the chance of patient’s survival and thus decreasing the breast cancer mortality.
By design of the HIP screening trial, women in the study group were offered
four screening examinations for the breast cancer. This took place in the first
4.5 years of the screening trial. After this period no woman in the study group
were offered any additional screening. Thus to compare the study group and the
control group, we use only the cancer cases detected during this 4.5 year period
in all groups as our cohorts.
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The HIP study recorded all breast cancer cases during the length of study
which include the screening period and the follow-up period. The cancer cases
detected during the follow-up period will be studied separately.
We should note that the determination of the actual time of the screening
period of 4.5 years is not without complications. There are several reasons why
we choose 4.5 years.
The entry date to the HIP study for each woman were varied. For women
in the study group, the entry date can be different from the initial screening
examination date. Moreover, although the screening period for each woman in the
study group should be three years with about one year difference between annual
screening examinations, the HIP data revealed a rather different picture. The
annual schedule was not always followed. In a number of cases the time between
scheduled annual screening examination greatly surpassed one year. In fact the
last screen-detected breast cancer occurred in the 50th month since her entry
date. This was 4.17 years after the entry, not the 3 years as scheduled. Table 2.1
presents the data of the time between entry to initial screening examination and
also between screening examinations.
As can be seen in Table 2.1, it took 66 months or 5.5 years from the entry date
for women in study group to complete all screening examinations. However, we
believe that using 66 months to determine the screening period is not reasonable
because the screening period would then be stretched to an unreasonable length.
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Table 2.1: Time in Months from Entry to Initial Screening and between Screening
Examinations
Average Std Dev Min Max
Entry to initial screening 0.78 1.502 0 18
Initial to 1st annual screening 13.50 1.756 7 23
1st annual to 2nd annual screening 13.42 1.615 1 23
2nd annual to 3rd annual screening 13.69 1.881 8 31
Entry to 3rd annual screening 40.99 3.386 32 66
Initial to 3rd annual screening 40.36 2.966 25 62
Std Dev = standard deviation, Min = minimum, Max = maximum
Table 2.1 shows that it took 18 months for all women who entered the study
group to complete the initial screening. In theory, it should take 36 months
for each woman to finish all three annual screening examinations. Therefore we
believe 54 months (18 + 36 months) or 4.5 years is a reasonable screening period
for the study group. Fortunately, the last screening detected case was diagnosed
in the 50th month after entry date, which is within the 54 months that we have
chosen. Thus, a 54 month screening period will be used in the comparison of
the study group, the control group and the refused group with respect to cancer
detection, mortality and survival. This establishes the cohorts for assessing the
efficacy of screening. Table 2.2 compares the breast cancer cases diagnosed during
the entire HIP study and during our screening period.
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Table 2.2: Comparison of Number of Breast Cancer Cases Diagnosed during HIP
Study and Screening Period
Number of cancer cases diagnosed during
Group Total HIP study screening period
participants No of cases Percentage No of cases Percentage
Control 30,565 945 3.092% 268 0.877%
Study 20,147 681 3.380% 211 1.047%
Refused 9,984 280 2.804% 71 0.711%
The selection of time period for comparison of the study group and the control
group is crucial to the analysis. Other researchers who used the HIP data have
chosen different time periods in their analysis. Chu et al (1988) used 6 years since
entry as opposed to our 4.5 years. Their reason was that 6 years was the earliest
time at which the number of breast cancer cases diagnosed in the control group
and the study group were equal. Shapiro (1989) used all cancer cases diagnosed
in 5 and/or 7 years after the entry date as the research subjects. Other periods
such as 10 years were also used in the literature. See, for example Shapiro et
al (1982). Inclusion of cancer cases detected during the follow-up period (not
obtained by screening) would water down the effect of screening and hence bias
the assessment of the efficacy of screening.
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2.3 Detection Stage
In the HIP study, the detection stage of each woman was recorded. The criteria
used for classification is as follows:
Stage I No microscopic evidence of axillary lymph node metastasis; no skin in-
volvement; no pectoral muscle or chest wall attachment; no distant metas-
tasis.
Stage II Positive microscopic evidence of axillary lymph node metastasis; no
skin involvement; no pectoral muscle or chest wall attachment; no distant
metastasis.
Stage III Axillary lymph nodes may be microscopically negative, positive or
unknown; evidence of skin involvement - erythema, infiltration, ulceration,
peau d’orage, edema; or pectoral or chest wall attachment; or clinically
palpable supraclavicular lymph node(s) with positive microscopic evidence
of metastasis; or axillary lymph nodes fixed to one another or to other
structures; no distant metastasis.
Stage IV Positive evidence of distant metastasis, radiographically or histologi-
cally confirmed.
In addition to these 4 stages, there are two other classifications used in the
HIP study. One is “Clinical Stage I or II”, the other is “unknown”.
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Clinical stage I or II is an invented stage, there were no axillary lymph nodes
removed. The only way to distinguish between stage I and stage II is by looking
at the lymph nodes. Since there were no axillary lymph nodes removed, there
was no way of knowing for sure whether it was stage I or stage II. However, there
was no demonstrable evidence of stage III or stage IV cancer. Thus it could not
be stage III or stage IV.
Women whose detection stage were unknown are categorized as “unknown”.
There are some examples of such cases in Section 2.4.
There are only a few clinical stage I or II cases, thus for analysis purpose
clinical stage I or II detections were combined with stage I detection.
2.4 Compliance of Women in the Study Group
In this section, we examine data on the compliance of women in the study group.
The screening pattern of all women in the study group is given in Figure 2.1.
Note that women in the study group who were diagnosed with breast cancer
on one of the screening examinations or between examinations would not attend
the ensuing screening examination. For instance, a woman who was diagnosed
with the breast cancer on the initial screening would have no need to come to
any of the subsequent annual screenings. The proportion of non compliance were
affected by this. However, it should be noted that the proportion of all cancer
cases in the study group is 3.380%, which is relatively small.
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Figure 2.1: Compliance of All Women in the Study Group
Percentage 59.38% 8.51% 3.94% 7.25% 3.29% 2.09% 2.40% 13.13%
Total 20147
No of women 11963 1715 793 1461 663 422 484 2646
Pattern 1111 1110 1101 1100 1011 1010 1001 1000
Third annual 1 0 1 0 1 0 1 0
Second annual 1 0 1 0
First annual 1 0
initial 1
It is very interesting to note that four cases in the study group have no
histologic confirmation prior to death, that is the cancer stage at detection is
unknown, even though the cause of death was breast cancer. Further investigation
revealed that one woman only went to the initial screening, one woman went to
the initial and first annual screenings, one woman went to the initial, first and
second annual screenings and one woman went to all four screenings. These
women were recommended to have biopsy or aspiration but none of them did it.
Breast cancer was listed as their as cause of death.
From Figure 2.1, one sees that aside from a handful number of women who
were diagnosed with breast cancer on screening or on early recall, only 59.38%
(11,963 out of 20,147) women in the study group went to all four screening ex-
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aminations. Initially, there were 30,131 women in the supposed study group. If
we take the proportion of women who attended all four screening examinations
with respect to these 30,131 women, only about 39.70% of women in the sup-
posed study group complied with screening protocol. Future studies on efficacy
of breast cancer screening should take this drastic reduction in sample size in the
study group into consideration. In the screening design, more women should be
assigned to the the study group in order to maintain a reasonable sample size for
the study group for comparison with the control group.
2.5 Summary of the Data of the Control, Study
and Refused Groups
Control Group Women in this group did not receive screening examinations.
There are 30,565 women participants in this group. Among them, 268
women were diagnosed with breast cancer during the next 4.5 years after
entry which corresponded to the screening period for the study group. In
contrast 945 were diagnosed with cancer during the entire 18 years of the
HIP study. Among these 268 cancer cases, by the end of the HIP study
97 survived, 147 died from breast cancer and 24 died from other causes
causes. The average entry age of the control group is 50.90 years with a
standard deviation of 6.577 years, while the average entry age of cancer
19
cases diagnosed during screening period in the control group is 52.31 years
with a standard deviation of 6.587 years.
Study Group Women in this group received screening examinations. There are
20,147 women in the study group. Among them, 211 women were diagnosed
with breast cancer during the screening period. In contrast 681 women of
this group were diagnosed during the entire HIP study. Out of 211 cancer
cases in this group, by the end of the HIP study 93 survived, 84 died from
breast cancer and 34 died from other causes. The average entry age of the
whole study group is 50.74 years with a standard deviation of 6.524 years,
while the average of entry age of cancer cases diagnosed during screening
period in the study group is 52.47 years with standard deviation of 6.501
years.
Refused Group Women in this group were offered but refused screening exam-
inations. There are 9,984 women in this group. During the screening period
71 women were diagnosed with the breast cancer. In contrast, during the
whole HIP study, 280 women were diagnosed with cancer. Out of 71 cancer
cases, by the end of the HIP study 23 survived, 33 died from breast cancer
and 15 died from other causes. The average entry age of the whole the
refused group is 51.11 years with a standard deviation of 6.608 years, while
the average entry age of cancer cases detected during screening period in
the refused group is 51.55 years with a standard deviation of 6.129 years.
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Table 2.3: Number Cancer Cases during Screening Period by Status at the End
of HIP Study
Total Survival Breast cancer death Other causes death
Group cases N Percentage N Percentage N Percentage
Control 268 97 36.19% 147 54.85% 24 8.96%
Study 211 93 44.08% 84 39.81% 34 16.11%
Refused 71 23 32.39% 33 46.48% 15 21.13%
N = no of cases
Table 2.3 and Table 2.4 present brief summaries of these three groups.
It is important to note that HIP has no record of the remission or recurrence
of those cancer cases. Thus for women who died from breast cancer, we have no
knowledge whether the breast cancer is a first-case breast cancer or a re-occurring
cancer. Also, for women who survived breast cancer, we do not know if the cancer
was in remission or has recurred.
As mentioned above, the entry age of the women participating in this study
was between 40-64 years with an average of 50.88 years and a standard deviation
of 6.565 years. The length of the HIP study itself is around 18 years. By the
end of the HIP study, the age of the women participants was around 58-82 years.
Thus some participants are quite advanced in age and this can affect their health
situation as a whole.
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Table 2.4: Average and Standard Deviation of Entry Age in Year
Cancer cases during
Group All Women screening period
N Average Std Dev N Average Std Dev
Control 30,565 50.90 6.577 268 52.31 6.587
Study 20,147 50.74 6.524 211 52.47 6.501
Refused 9,984 51.11 6.608 71 51.55 6.129
Std Dev = standard deviation
We have compared the entry age and also compared the proportions of the
breast cancer cases diagnosed during screening period among groups.
We use ANOVA to test if the average entry ages are significantly different
among groups. If so, Tukey’s confidence intervals are produced to investigate in
which pair of groups the different exist.
The first ANOVA is conducted using the entire HIP data. It shows that dif-
ferences of the average entry ages among groups is significant at 5% level (the F
statistic is 10.54 with 2 degrees of freedom which gives a p-value of < 0.0001).
Using Tukey’s simultaneous confidence intervals, we find that the average differ-
ence of entry age between the control group and the study group is 0.160 year
with 95% confidence interval of (0.020, 0.300), the average difference of entry
age between the control group and the refused group is -0.204 year with 95%
confidence interval of (-0.381, -0.027) and the average difference between the
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study group and the refused group is -0.364 years with 95% confidence interval
of (-0.552, -0.176).
In contrast, the second ANOVA applied to entry age of the breast cancer
cases diagnosed during screening period shows no significant entry age differences
among three groups (the F statistic is 0.54 with 2 degrees of freedom which gives
a p-value of 0.5825).
The proportions of breast cancer diagnosed during the screening period in the
control group, the study group and the refused group are 0.877%, 1.047% and
0.711% respectively. The pairwise comparisons show that:
(1) The difference of proportions between the control group and the study group
is -0.0017 with a standard error of 0.0009 and the an 95% asymptotic con-
fidence interval of (-0.0035, 0.0000). Since the confidence interval contains
zero, the proportion difference is not significant at 5% level.
(2) The difference of proportions between the control group and the refused
group is 0.0017 with a standard error of 0.0010 and an 95% asymptotic
confidence interval of (-0.0003, 0.0036). The difference is not significant.
(3) The difference of proportions between the study group and the refused
group is 0.0034 with a standard error of 0.0011 and a 95% asymptotic
confidence interval of (0.0012, 0.0055). Hence the proportion difference is
significant.
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Even though the proportion difference between the control group and the
study group is not significant, there were indeed more breast cancer cases detected
in the study group compared to the control group. This possibly indicates that
annual screening causes a shift in the detection time.
Throughout the thesis, it is to be understood that the study sample is limited
to those women whose breast cancer was detected during this screening period,
unless noted otherwise. Also, all tests are conducted with a 5% level of signifi-
cance, unless noted otherwise.
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Chapter 3
Comparison of Proportions of Cancer Mortality, Survival
and Deaths from Other Causes
As discussed in Chapter 1, in any group each cancer patient had one of three
possible outcomes by the end of the HIP study. A patient can be either alive,
or die from breast cancer, or die from other causes. Although there were several
participants lost to follow-up in the HIP project, fortunately there are no women
lost to follow-up for the particular data set used in this thesis.
In this chapter, we compare the proportions of women in each of the three
possible outcomes among the control group, the study group and the refused
group. If screening examination does lead to early detection of the breast cancer
which in turn lead to better survival probability, we would then see a larger
proportion of breast cancer survivors in the study group as compare to the control
group and probably the refused group. We would also expect to see a smaller
proportion of breast cancer deaths in the study group than in the control group
and probably the refused group. As for deaths due to other causes, it is likely
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that we would see a larger proportion of it in the study group than in the control
group because those cancer survivors in the study group would die from other
causes.
The proportions of the three possible outcomes for all three groups in the HIP
data were given in Table 2.3.
3.1 Test of Equality of Proportions
We test the hypothesis of equality of proportions based on a multinomial distri-
bution of three possible outcomes at the end of the HIP study. The test will then
be followed by pairwise comparison tests of equality of proportions. The result
will give us a sense as to which pairs are different.
We first compare all three groups. Let pA−C , pA−S and pA−R be the respective
true proportions of women who survived breast cancer in the control group, the
study group and the refused group by the end of the follow-up. Similarly, let pB−C ,
pO−C , pB−S, pO−S, pB−R, pO−R denote the respective proportions of women who
died from breast cancer and from other causes in the control group, the study
group and the refused group. Then the hypothesis to be tested is
H0 : pA−C = pA−S = pA−R, pB−C = pB−S = pB−R, pO−C = pO−S = pO−R
versus the alternative
HA : H0 is not true.
26
The chi-square statistic yields 16.6877 with 4 degrees of freedom which gives a
p-value of 0.0022. Thus we reject the null hypothesis of equal proportions at the
5% level.
However, this test does not give us a sense as to which pairs are different.
Thus we conduct a pairwise comparison between each pair of two groups. Since
each group is used twice in the pairwise comparison, the resulting three tests
involved the same data sets and hence are not statistically independent. By
invoking Bonferroni’s inequality, if we set the level of significance of each separate
pairwise test to be 0.05/3 = 0.0167, we can claim that the level of significance of
the test of equality of all three pairs is no larger than 0.05.
We first compare the control group and the study group. the hypothesis to be
tested is H0 : pA−C = pA−S, pB−C = pB−S, pO−C = pO−S versus the alternative
HA : H0 is not true. The chi-square statistic yields 12.383 with 2 degrees of
freedom which gives a p-value of 0.002. We reject the null hypothesis of equal
proportion at level 0.0167.
Similar tests were also conducted to compare the control group and the refused
group, and also the study group and the refused group.
The test shows that the control group and the refused group have significantly
different proportions. The chi-square statistic is 8.198 with 2 degrees of freedom
which gives p-value of 0.0166.
27
In comparison of the study group and the refused group, the chi-square statis-
tic is 3.100 with 2 degrees of freedom which gives a p-value of 0.2122. Thus the
null hypothesis of equal proportions is not rejected at level 0.0167.
Based on these results, we can say that the refused group is “closer” to the
study group than to the control group. This conclusion is surprising since this
seems counter intuitive. Intuitively, since the women in the refused group did not
have screening, we expected the result to be similar to that of the control group.
Further tests of proportions were performed to investigate in which direction
the proportions differ.
3.2 Separate Comparisons of Single Outcome
Variables
We will compare each of the three outcome variables separately the in two groups
(pairwise) at a time. We will compare the control group and the study group,
and compare the control group and the refused group. Since the test in the last
section did not reject the equality of two trinomial distributions of proportions
of the study and refused groups, we will not conduct a pairwise comparison of
the study group and the refused group.
The deaths from other causes complicate our comparisons of the breast cancer
survival proportion and breast cancer death proportion. The HIP data does not
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contain any information about the curing (cancer in remission) and reoccurring
of the breast cancer and thus it is not possible to ascertain the disease status
(with respect to the breast cancer) of those women who died from other causes.
In the absence of such information, we consider two approaches. In the first
approach, we treat each outcome variable separately. In the second approach, we
treat the data of death from other causes as censored survival data because they
were diagnosed with cancer and were alive until their death due to other causes.
Thus their lifetimes are censored observations with respect to the breast cancer
survival.
3.2.1 Comparison of Breast Cancer Mortality in Different
Groups
Referring to Table 2.3, the proportions of death from breast cancer among women
diagnosed with the breast cancer in the control group, the study group and the
refused group are 0.5485 (147/268), 0.3981 (84/211) and 0.4648 (33/71) respec-
tively.
The binomial test shows a significant difference in the proportion of breast
cancer death in the control group and the study group. The proportion of breast
cancer death is 0.1504 lower in the study group. The standard error of the dif-
ference is 0.0454 with an asymptotic 95% confidence interval of (0.0615, 0.2394).
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The Mantel-Haenszel relative risk for these two groups is 1.3778 with 95%
confidence interval of (1.1300, 1.6800). This means that women diagnosed with
the breast cancer during screening period in the control group are 38% more
likely to die from breast cancer than those women in the study group by the end
of the follow-up.
However, the test shows no significant difference in the breast cancer death
proportion between the control group and the refused group at 5% level.
3.2.2 Comparison of Proportion of Death from Other Causes
Referring to Table 2.3, the proportions of death from other causes in the con-
trol group, the study group and the refused group are 0.0896 (24/268), 0.1611
(34/211) and 0.2113 (15/71) respectively.
The difference in proportions between the control group and the study group
is significant. The proportion of deaths from other causes is 0.0716 higher in the
study group. The standard error of the difference is 0.0307 with an asymptotic
95% confidence interval of (0.0113, 0.1318).
The difference in proportions of deaths from other causes is significant between
the control group and the refused group. The proportion of deaths due to other
causes is 0.1217 higher in the refused group. The standard error of the difference
is 0.0515 with an asymptotic 95% confidence interval of (0.0208, 0.2226).
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It is important to note that there are 7.16% more women in the study group
who died from other causes compared to the control group. As mentioned previ-
ously, this can be interpreted as saying that early detection of breast cancer by
screening in the study group results in higher probability of recovery (or cancer
in remission) from the breast cancer but then those women eventually died from
other causes.
3.2.3 Comparison of Survival Proportions
From Table 2.3, the proportions of women who survived the breast cancer in the
control group, the study group and the refused group are 0.3619 (97/268), 0.4408
(93/211) and 0.3239 (23/71) respectively.
Even though the survival proportion in the study group is 0.0788 higher com-
pare to that in the the control group, the test shows that the result is not sig-
nificant at 5% level. The standard error is 0.0451 with an asymptotic 95% con-
fidence interval of (-0.0095, 0.1671). Although the result is not significant, the
lower bound of the confidence interval, which is -0.0095, is quite close to zero.
Also, there is no significant difference between the control group and the
refused group proportion at the 5% level.
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3.2.4 Treatment of the Death Due to Other Causes
In this subsection, we consider two different ways of treating the death due to
other causes. Our first approach is to completely ignore the category of death
from other causes in the calculation of the breast cancer mortality. Our second
approach is to treat the times to death due to other causes as censored survival
times. This is because an individual who died from other causes was alive as
a breast cancer patient until her time of death, and her survival time was then
censored at the time of her death. Either approach will give us two mutually
exclusive outcome events. A women would then either die from breast cancer
or survive breast cancer with a censored survival time. Thus comparing survival
proportion is equivalent to comparing the breast cancer death proportion. We
shall compare the survival proportion. Note that either approach would result in
a modification of the original data.
The first approach will reduce sample sizes in the three groups, so they need
to be recalculated. Referring to Table 3.1, in the control group 244 women were
diagnosed with breast cancer during screening period. By the end of the HIP
study, there were 97 survivors and 147 women who died from breast cancer.
While in the study group, 177 women were diagnosed with breast cancer during
the screening period of whom 93 survived and 84 died from the breast cancer.
Lastly, in the refused group, there were 23 women who survived and 33 who died
from breast cancer, making a total of 56 women.
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Table 3.1: Number Cancer Cases during Screening Period by Status at the End
of the Follow-up
Group Total no No of No of breast
of cases survival cancer deaths
Control 244 97 147
Study 177 93 84
Refused 56 23 33
The survival proportions in the control group, the study group and the refused
group then become 0.3975, 0.5254 and 0.4107 respectively.
The control group and the study group showed a significant result at 5% level.
The survival proportion in the study group is 0.1279 (standard error is 0.0489)
higher than in the control group. An asymptotic 95% confidence interval for the
difference of survival proportions is (0.0321, 0.2237). Furthermore, the Mantel-
Haenszel relative risk for these two groups is 1.2695 with the 95% confidence
interval of (1.0545, 1.5282). In other words, it can be said that women diagnosed
with breast cancer during screening period in the study group are 27% more likely
to survive breast cancer than those women in the control group.
For the study group and the refused group comparison, and also the control
group and the refused group comparison, the tests show no significant differences
at 5% level.
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Table 3.2: Number Cancer Cases during Screening Period by Status at the End
of the Follow-up
Group Total no No of No of breast
of cases survival cancer deaths
Control 268 121 147
Study 211 127 84
Refused 71 38 33
The second approach for comparing proportions of women who survived breast
cancer is conducted by combining death times from other causes with the survival
times. Table 3.2 gives the recalculated number of cases. Under this approach,
in the control group there were 121 women survived breast cancer (censored
survival times) and 147 who died from breast cancer which gives a total of 268
women diagnosed with the breast cancer. In the study group there are 211 women
diagnosed with breast cancer of whom 127 survived and 84 died. Lastly, in the
refused group, there were a total of 71 women diagnosed with breast cancer of
whom 38 survived and 33 died.
The survival proportions in the control group, the study group and the refused
group are 0.4515, 0.6019 and 0.5352 respectively.
For the control group and the study group comparison, the test shows a signif-
icant difference at 5% level. The survival proportion in the study group is 0.1504
(with standard error 0.0454) higher than in the control group. A 95% confidence
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interval for this difference is (0.0615, 0.2394). The Mantel-Haenszel relative risk
for these two groups is 1.3778 with 95% confidence interval of (1.1300, 1.6800).
Thus we can also conclude that women in the study group are 38% more likely
to survive cancer than those in the control group.
The test showed no significance difference between the study group and the




Comparison of Total Years Lived and Kaplan-Meier
Estimate of Survival Function
In this chapter, we shall assess the effect of screening in terms of the total years
lived and the Kaplan-Meier estimate of the survival function.
4.1 Comparison of Total Years Lived
For women who survived breast cancer by the end of the follow-up, the total
years lived is defined as the length of time from the diagnosis of breast cancer to
the end of the follow-up. For women who died either from breast cancer or from
other causes before the end of the HIP study, the total years lived is defined as
the length of time from the diagnosis of breast cancer to the time of death.
Since the age range (from 40 to 64 years of old) of women in the HIP study
is fairly large, the overall (or natural) death rate increases significantly with the
advancing age. To account for the age differences, another way of defining the
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total years lived is used by some researchers. It is measured from the time of
birth to either the time of death or the end of the follow-up if the woman is still
alive.
In either case, if screening is beneficial, we would expect that the average of
total years lived in the study group to be longer than that of the control group
and probably the refused group. However one should keep in mind that the total-
years-lived is measured up to the end of the follow up time. It does not represent
the total lifetime of a patient
Comparison of the total years lived is complicated by the fact that a woman
may die from other causes. Because HIP has no record of these women with
respect to their breast cancer history and survival experience, we shall treat this
type of death times as censored survival times.
Comparisons of the averages of total years lived in the three groups are car-
ried out by using ANOVA. If ANOVA shows a significant result, then Tukey’s
construction of confidence intervals of all possible pairwise average differences
between groups will be calculated, namely the difference between the study and
control groups, the study and refused groups and the control and refused groups.
These confidence intervals will be referred to as simultaneous confidence intervals.
They are calculated to examine in which pairs the difference exist.
A five percent level of significance will be used throughout and hence it will
not always be mentioned.
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Table 4.1: Average and Standard Deviation of Total Years Lived after Detection
for All Cancer Cases
All cases
Group Number of cases Average Std Dev
Control 268 9.00 6.760
Study 211 11.11 6.042
Refused 71 9.03 6.755
Std Dev = standard deviation
4.1.1 Comparison of Total Years Lived after Cancer De-
tection
An ANOVA of the data presented in Table 4.1 shows that there is a significant
difference among the three groups in the averages of the total years lived after
detection (to be called averages for short in this section whenever no ambiguity
arises). The F statistic is 6.86 with 2 degrees of freedom which gives a p-value of
0.0011. The Tukey pairwise test showed that the average difference between the
control group and the study group is significant. The average in the study group
is 2.1158 years longer than that in the control group. The Tukey 95% confidence
interval for the true average difference is (0.7114, 3.5203). On the other hand,
the pairwise test shows no significant difference in averages between either the
control group and the refused group or the study group and the refused group.
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Note that at the end of HIP study there are three possible outcomes for
women diagnosed with the breast cancer: survival, death from breast cancer or
death from other causes. Since there is no information recorded on the cancer
development of those women who died from other causes, we are again faced
with the problem of how to properly utilize the death times of these women. We
decided to treat them as a separate case. The following refinement of ANOVA is
conducted separately for deaths due to breast cancer, survivals and combination
of deaths due to breast cancer and survivals outcomes. Table 4.2, Table 4.3 and
Table 4.4 contain the averages and standard deviations for various combinations
of group and outcome. Table 4.4 excludes deaths from other causes. The ANOVA
was not conducted for deaths from other causes, because deaths from other causes
give us no information on breast cancer survival experience. Even though no
analysis was conducted for deaths due to other causes, the averages and standard
deviations were given in Table 4.5.
Death from Breast Cancer The data are presented in Table 4.2. The ANOVA
for death from breast cancer shows significant differences among the three
groups at 5% level. The F statistic is 4.19 with 2 degrees of freedom which
give a p-value of 0.0162. The Tukey pairwise comparison shows that a sig-
nificant difference in the averages of the total years lived between the study
group and the control group. The average of the study group is 1.4087
years longer than that of the control group with a 95% confidence interval
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Table 4.2: Average and Standard Deviation of Total Years Lived after Detection
for Women Who Died from Breast Cancer
Breast cancer death
Group Number of cases Average Std Dev
Control 147 4.20 3.977
Study 84 5.61 4.173
Refused 33 3.68 3.988
Std Dev = standard deviation
Table 4.3: Average and Standard Deviation of Total Years Lived after Detection
for Women Who Survived
Group Survival
Number of cases Average Std Dev
Control 97 16.63 1.584
Study 93 16.62 1.449
Refused 23 16.63 1.508
Std Dev = standard deviation
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Table 4.4: Average and Standard Deviation of Total Years Lived after Detection
for Breast Cancer Death and Survival Combined
Group Death from Breast Cancer and Survival
Number of cases Average Std Dev
Control 244 9.14 6.903
Study 177 11.40 6.303
Refused 56 9.00 7.175
Std Dev = standard deviation
Table 4.5: Average and Standard Deviation of Total Years Lived after Detection
for Women Who Died from Other Causes
Group Other Causes Death
Number of cases Average Std Dev
Control 24 7.49 4.941
Study 34 9.62 4.210
Refused 15 9.14 5.085
Std Dev = standard deviation
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of the true average difference (0.1057, 2.7117). However, Tukey’s method
shows no significant difference in averages in all other pairwise comparisons
of two groups.
Survival The data are presented in Table 4.3. ANOVA shows no significant
differences in the averages of total years lived among the survivals in the
three groups. The F statistic is 0.00 with 2 degrees of freedom which give a
p-value of 0.9991. We expect this result because the women are all censored
by end of follow-up.
Combined Data of Deaths from Breast Cancer and Survivals The data
are presented in Table 4.4. The ANOVA for the two combined outcomes
shows a significant difference in averages of total years lived since detection
among three groups. The F statistic from the ANOVA is 6.42 with 2 de-
grees of freedom, which gives a p-value of 0.0018. The results of the Tukey
pairwise comparison of the averages of total years lived are as follows. The
average difference between the control group and the study group is signifi-
cant at 5% level. The average of the study group is 2.2534 years longer than
that of the control group with a 95% confidence interval of the true average
difference (0.6935, 3.8132). The tests showed no significant differences in
the averages of total years lived between the control and the refused group,
and also between the study and the refused group.
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Table 4.6: Average and Standard Deviation of Total Years Lived after Birth for
All Cancer Cases
Group All cancer cases
Number of cases Average Std Dev
Control 268 64.03 9.287
Study 211 66.02 9.036
Refused 71 63.38 8.077
Std Dev = standard deviation
4.1.2 Comparison of Total Years Lived Measured from
the Time of Birth
The summary statistics of total years lived since the time of birth is given in
Table 4.6. Data analyses similar to those in the previous section for the total
years lived since cancer detection were performed.
The ANOVA for the averages of total years lived since birth (to be called
averages in this section when no ambiguity arises) shows a significant difference
among three groups at 5% level. The F statistic is 3.71 with 2 degrees of freedom
which gives a p-value of 0.0250. The Tukey pairwise comparison shows that there
is a significant difference in averages between the study group and the control
group. The average of the study group is 1.9821 years longer than that of the
control group. The 95% confidence interval for the true average difference is
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Table 4.7: Average and Standard Deviation of Total Years Lived after Birth for
Women Who Died from Breast Cancer
Group Breast cancer death
Number of cases Average Std Dev
Control 147 58.77 7.354
Study 84 60.09 8.366
Refused 28 58.65 7.018
Std Dev = standard deviation
(0.0259, 3.9384). On the contrary, no significant differences were detected in
other pairwise comparisons.
Table 4.7, Table 4.8, Table 4.9 and Table 4.10, contain the averages and
standard deviations for different outcomes at the conclusion of the HIP study.
As in Subsection 4.1.1, the ANOVA and Tukey pairwise comparisons of total
years lived since birth are conducted for deaths due to breast cancer, survivals
and combination of deaths due to breast cancer and survivals.
Death from Breast Cancer The ANOVA of the data in Table 4.7 shows no
significant differences in averages of the total years lived since birth in the
three groups. The F statistic is 0.89 with 2 degrees of freedom which gives
a p-value of 0.4129.
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Table 4.8: Average and Standard Deviation of Total Years Lived after Birth for
Survival
Group Survival
Number of cases Average Std Dev
Control 97 71.64 6.357
Study 93 71.13 6.377
Refused 23 69.25 5.363
Std Dev = standard deviation
Table 4.9: Average and Standard Deviation of Total Years Lived after Birth for
Women Who Either Died from or Survived Breast Cancer
Group Breast Cancer Death and Survival
Number of cases Average Std Dev
Control 244 63.89 9.398
Study 177 65.89 9.210
Refused 56 63.00 8.239
Std Dev = standard deviation
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Table 4.10: Average and Standard Deviation of Total Years Lived after Birth for
Women Who Died from Other Causes
Group Other causes death
Number of cases Average Std Dev
Control 24 65.52 8.100
Study 34 66.67 8.167
Refused 15 64.79 7.537
Std Dev = standard deviation
Survival Referring to Table 4.8, The ANOVA shows no significant differences in
averages among groups. The F statistic is 1.35 with 2 degrees of freedom
which give a p-value of 0.2607.
Combined Data of Death from Breast Cancer and Survivals The data are
presented in Table 4.9. The ANOVA shows that there is a significant differ-
ence in the averages of the total years lived since birth among three groups.
The F statistic is 3.30 with 2 degrees of freedom which gives a p-value of
0.0376. However, there are no significant results from the Tukey pairwise
average comparison between any two groups.
We have some very interesting facts here. There are significantly fewer breast
cancer deaths and more breast cancer survivors in the study group than that of
the control group. But the number of deaths :from other causes is significantly
46
higher in the study group than that in the control group. A plausible explanation
is that women in the study group survived breast cancer but then died from other
causes and hence had a higher mortality from other causes. However, neither the
average of total years lived after detection nor the average of total years lived
since birth of cancer survivors in the study group is significantly different from
those in the control group. As for women who died from breast cancer, the
averages of total years lived after birth are about the same in both the study
and the control groups. But the study group has a significantly longer average of
total years lived after detection than that of the control group.
A plausible explanation is that those who survived breast cancer in the control
group were diagnosed at an early stage as was expected to happen in the study
group, thus the total years lived after detection and the total years lived after
birth are not significantly different. It would be interesting to investigate what
happens when the analysis is conducted by the stage of the breast cancer at
detection time.
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4.2 Kaplan-Meier Estimator of Survival Func-
tion
4.2.1 Estimator of the Survival Function of the Breast
Cancer Patients
A cancer patient may either die from breast cancer or from other causes or be
alive at the end of the follow-up period. We are interested in the time X, which
measures the time of a cancer patient from diagnosis to death from breast cancer.
If the cancer patient dies from other causes or is alive at the end of the follow-up,
let Y denote either the time from her diagnosis to death of from other causes
or to the end of the follow-up if she is still alive. Here, we treat Y as a right
censoring variable for X. The right censored data are min(X, Y ) and the indicator
I[X ≤ Y ]. The Kaplan-Meier estimate of the survival function S(t) = P [X > t]
of X for each group constructed from the censored data is given in Figure 4.1.
Figure 4.2 shows the censoring time for each group.
Confidence bands for the Kaplan-Meier estimate of the survival distribution
of X are produced using the Hall-Wellner method and are given in Figure 4.3,
Figure 4.4 and Figure 4.5.
Figure 4.1 shows that the study group always has a better survival probability
than that of the control group and the refused group. We conduct a generalized
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Figure 4.1: Kaplan-Meier Estimates of Survival Functions
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Figure 4.2: Censoring Pattern
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Figure 4.3: Hall-Wellner Confidence Bands for the Control Group
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Figure 4.4: Hall-Wellner Confidence Bands for the Study Group
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Figure 4.5: Hall-Wellner Confidence Bands for the Refused Group
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Wilcoxon test (for right-censored data) to investigate if this difference is signifi-
cant. Let FC and FS be the respective distribution function of X for the control
group and the study group. The hypothesis to be tested is H0 : FC = FS versus
the alternative HA : H0 is not true. The Wilcoxon test statistic has an asymptotic
chi-square distribution with 1 degree of freedom.
The Wilcoxon test yields a test statistic of 17.4663 which gives a p-value of
< 0.0001. Thus the distribution function of X of the control group is significantly
different at the 5% level from that of the study group.
Similar test showed no significant difference in distributions between the con-
trol group and the refused group. The test statistic is 0.2610 which gives a p-value
of 0.6095.
However, the distribution function of X of the study group is significantly
different (at the 5% level) from that of the refused group. The test statistic is
4.6019 which yields a p-value of 0.0319.
4.2.2 Kaplan-Meier Estimate of Survival Function by Stage
The higher survival probability in the study group than that of the control group
can be attributed to the fact that the study group has a higher proportion of
early detection than that of the control group. This is studied in Chapter 5.
We would like to see how the Kaplan-Meier estimate of the survival function
estimate changes when the data is analyzed by detection stage. It can be seen
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in Table 5.1 that there are only a handful of women diagnosed beyond stage II.
Because the sample size of the stages beyond II is too small for statistical analysis,
the Kaplan-Meier estimate of the survival function will only be produced for the
breast cancer cases diagnosed in stage I and stage II. As mentioned in Section 2.3,
clinical stage I or II detection cases were combined with stage I detection cases.
For simplicity, the combination of stage I detection and clinical stage I or II
detection is called “combined stage I” detection.
The survival function for combined stage I detected patients is given in Fig-
ure 4.6 and the censoring pattern is given in Figure 4.7. In the refused group,
there are only 2 breast cancer deaths, thus the survival curve is flat from time
2.5 years on. The confidence bands for the survival functions of combined stage
I detection for the control group and the study group are given in Figure 4.8 and
Figure 4.9.
Figure 4.6 clearly shows that for patients detected at combined stage I the
study group has a better survival probability than that of the control group,
especially in the first 10 years. A generalized Wilcoxon test is conducted to
compare the distribution function of X of the control group and the study group.
The test turns out to be not significant. The test statistic is 2.4668 which yields
a p-value of 0.1163.
For patients detected at stage II, the survival function is given in Figure 4.10,
while the censoring pattern is given in Figure 4.11. The confidence bands for the
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Figure 4.6: Kaplan-Meier Estimates for Combined Stage I Detection
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Figure 4.7: Censoring Pattern for Combined Stage I Detection
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Figure 4.8: Hall-Wellner Confidence Bands for Combined Stage I Detection in
the Control Group
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Figure 4.9: Hall-Wellner Confidence Bands for Combined Stage I Detection in
the Study Group
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Figure 4.10: Kaplan-Meier Estimates for Stage II Detection
survival functions of stage II detection for the control group and the study group
are given in Figure 4.12 and Figure 4.13.
Comparing Figure 4.6 and Figure 4.10, it can be easily seen that combined
stage I detection has a much better survival probability than that of stage II
detection. Although the study group has better survival curves in both stage
I and II, than that of the control group, formal hypothesis testing showed no
significant difference in the distribution function of X in the study and control
groups. As in stage I detection, the test statistic is 2.7855 which gives a p-value
of 0.0951.
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Figure 4.11: Censoring Pattern for Stage II Detection
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Figure 4.12: Hall-Wellner Confidence Bands for Stage II Detection - the Control
Group
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Analysis of the Stage of Breast Cancer at Detection
The screening program is conducted on the assumption that breast cancer will
be diagnosed at early stages of the disease development. Thus we would expect a
larger proportion of early detection of breast cancer cases in the study group than
in the control group. Table 5.1 gives the proportion of cancer detections by stage
in the control group, the study group and the refused group. It is interesting
to note that 63.98% of the cancer cases in the study group were detected at
stage I, in contrast to 44.78% and 39.44% of the cancer cases detected in the
control group and the refused group, respectively. This supports the belief that
screening results in early detection of breast cancer. Formal statistical analysis
will be conducted in subsequent sections.
However, it is surprising to see that some cancer cases in the study group
were diagnosed in much later stages, that is, stage III or stage IV. Nonetheless,
their percentages were small. There are several possible explanations for this.
One possible explanation is that the breast cancer screening missed the cancer
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Table 5.1: Breast Cancer Detection by Stage
Control Study Refused
Stage N % N % N %
Stage I 120 44.78% 135 63.98% 28 39.44%
Stage II 94 35.07% 55 26.07% 21 29.58%
Stage III 29 10.82% 9 4.27% 6 8.45%
Stage IV 6 2.24% 3 1.42% 10 14.08%
Clinical Stage I or II 14 5.22% 8 3.79% 4 5.63%
Unknown 5 1.87% 1 0.47% 2 2.82%
Total 268 211 71
N = no. of cases, % = percentage
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(false negative). Another is that some of the breast cancer cases diagnosed at
the initial screening were already at advanced stages. In fact, in the study group
44.44% (4 out of 9) of the stage III detections were diagnosed either at initial
screening or on early recall of the initial screening, while 33.33% (1 out of 3) of
the stage IV detection and 50% (4 out of 8) of the clinical stage I or II detection
were also diagnosed at initial screening.
5.1 Comparing the Distribution of Detection Stages
in the Three Groups
We perform statistical hypothesis testing to check if the distribution of the de-
tection stages are significantly different and if screening indeed leads to early
detection of breast cancer. By early detection, it is meant to detect in stage I or
II. Since there were only a few cancer cases detected in some advanced stages,
for hypothesis testing we combine more advanced stages into one to increase the
sample sizes. We shall call this combined category the advanced stages. Since
our primary interest is in early detection, combining more advanced stages will
not affect our investigation. As mentioned in Section 2.3, clinical stage I or II
detection cases were combined with stage I detection cases. For simplicity, the
combination of stage I detection and clinical stage I or II detection is called
“combined stage I”. Table 5.2 reflects these changes.
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Table 5.2: Breast Cancer Detection by Stage – Collapsed Cells
Control Study Refused
Stage N % N % N %
Combined Stage I 134 50.00% 143 67.77% 32 45.07%
Stage II 94 35.07% 55 26.07% 21 29.58%
Advanced stages 40 14.93% 13 6.16% 18 25.35%
Total 268 211 71
N = no. of cases, % = percentage
We first compare all three groups. Let pCS1−C , pS2−C and padv−C be the true
probabilities of detections in combined stage I, stage II and advanced stages in the
control group. Let pCS1−S, pS2−S, padv−S, pCS1−R, pS2−R and padv−R be similarly
defined for the study group and the refused group. The hypothesis to be tested
is H0 : pCS1−C = pCS1−S = pCS1−R, pS2−C = pS2−S = pS2−R, padv−C = padv−S =
padv−R versus the alternative HA : H0 is not true. The chi-square statistic yields
28.3772 with 4 degrees of freedom which gives a p-value of < 0.0001. Thus we
reject the null hypothesis of equal proportions at the 5% level.
However, this test does not give us a sense as to which pairs are different.
Thus we conduct a pairwise comparison with a smaller level of significance, that
is 1.67% level (5% divided by 3).
We first compare the control group and the study group. The hypothesis
to be tested is H0 : pCS1−C = pCS1−S, pS2−C = pS2−S, padv−C = padv−S versus
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the alternative HA : H0 is not true. For the hypothesis H0 of equal multinomial
distributions of the detection probabilities, the chi-square statistic is 17.7233
with 2 degrees of freedom, which gives a p-value 0.0001. Thus, we conclude that
the detection stage distributions in the control group and the study group are
significantly different at the 1.67% level.
A similar test also shows a significant difference between the study group and
the refused group at the 1.67% level. The test yields a chi-square statistic of
22.4531 with 2 degrees of freedom which gives a p-value < 0.0001.
But the test shows no significant difference in the detection stage distribution
between the control group and the refused group. The chi-square statistic is
4.3452 with 2 degrees of freedom which gives a p-value of 0.1139.
Next we investigate differences in the probability of the combined stage I
detection among the three groups. The sample proportion of combined stage
I detection in the control group, the study group and the refused group are
p̂S1−C = 0.5000, p̂S1−S = 0.6777 and p̂S1−R = 0.4507 respectively; see Table 5.2.
Comparison of the control group and the study group shows a significant
difference in the probability of combined stage I detection (the chi-square statistic
is 15.2904 with 1 degree of freedom which gives a p-value of < 0.0001). The
sample proportion of combined stage I detection in the study group is 0.1777
higher than that in the control group. The standard error of the difference of the
sample proportion is 0.0444 which gives an asymptotic 95% confidence interval of
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p̂CS1−S− p̂CS1−C (0.0908, 0.2647). Furthermore, the Mantel-Haenszel relative risk
for these two groups is 1.5515 with a 95% confidence interval (1.2334, 1.9515).
This means that the breast cancer cases in the study group are 55% more likely
to be diagnosed at stage I or clinical stage I or II than those in the control group.
The difference between the study group and the refused group is also signifi-
cant (the chi-statistic is 11.6279 with 1 degree of freedom which gives a p-value of
0.0006). The sample proportion of combined stage I in the study group is 0.2270
higher than that in the refused group with a standard error of the difference of the
two sample proportions equal to 0.0672 and an asymptotic 95% confidence inter-
val of (0.0952 0.3588) for the difference p̂CS1−S − p̂CS1−R. The Mantel-Haenszel
relative risk for these two groups is 1.7044 with a 95% confidence interval of
(1.2785, 2.2723). Thus the breast cancer cases in the study group are 70% more
likely to be diagnosed in stage I or clinical stage I or II than those cases in the
refused group.
The difference between the control group and the refused group is not signif-
icant.
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5.2 Analysis by Outcomes at the End of the
HIP Study and Total Years Lived
As discussed in previous sections, at the end of the follow-up period each patient
has one of the three possible outcomes: survival, death from breast cancer or
death from other causes. We have investigated in Chapter 4 the differences in
outcomes among the three groups. In this section, we carry out a more refined
study by examining the effect of early detection on the outcomes. Table 5.3
contains the sample proportions for each possible outcome in each particular
stage.
We shall use the data in Table 5.3 to compare the outcomes the patients
whose cancer were detected in combined stage I or stage II among the three
groups. These stages are deemed as early detections. Since only few cases were
detected in more advanced stages and since they are not our main interest, we
will not carry out the statistical analysis of cases.
For cancer detected in combined stage I, there was no significant difference in
the outcome probabilities between the control group and the study group. The
chi-square statistic is 1.7194 with 2 degrees of freedom which gives a p-value of
0.4233.
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Table 5.3: Breast Cancer Detection Stage by Outcomes at the End of the HIP
Study
Survival DBC DOC
Stage and Group N % N % N %
Control 75 55.97% 41 30.60% 18 13.43%
Combined Study 81 56.64% 36 25.17% 26 18.18%
Stage I Refused 18 56.25% 2 6.25% 12 37.50%
Control 21 22.34% 68 72.34% 5 5.32%
Stage II Study 12 21.82% 36 65.45% 7 12.73%
Refused 5 23.81% 13 61.90% 3 14.29%
Control 1 2.50% 38 95.00% 1 2.50%
Advanced Study 0 0.00% 12 92.31% 1 7.69%
Stages Refused 0 0.00% 18 100.00% 0 0.00%
N = no. of cases, % = percentage
DBC = death from breast cancer, DOC = death from other causes
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Also, there is no significant difference in outcome probabilities for cancer
detected in stage II between the control group and the study group. The chi-
square statistics is 2.6044 with 2 degree of freedom which give a p-value 0.2719.
The refused group has too few observations to carry out the statistical com-
parison with the two other groups.
It is interesting to note that for advanced stages detection, the proportions of
survival and deaths due to other causes are extremely small.
Table 5.4 contains the sample average and standard deviation of total years
lived after detection for all cancer cases broken down by detection stage. Table 5.5
contains the same information as in Table 5.4, only the information is further
broken down by the outcomes at the end of HIP study.
From inspection of Table 5.4, there seems to be little difference among groups
in the average of total years lived after detection for all cancer cases detected in
combined stage I. While for stage II and advanced stages detection, the average
of total years lived after detection in the control group is very close to that in
the study group. However, the refused group has a higher average for stage II
detection, and a lower average for advanced stages detection.
When the total years lived after detection is further broken down by outcomes
at the end of HIP study (Table 5.5), there is little difference in the average of
total years lived after detection for women who survived breast cancer regardless
the stage detection. We expect this because the total years lived for women who
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Table 5.4: Average and Standard Deviation of Total Years Lived after Detection
by Breast Cancer Detection Stage
Stage and All Cases
Group N Average Std Dev
Control 134 12.13 6.100
Combined Study 143 13.10 5.166
Stage I Refused 32 12.30 5.854
Control 94 7.00 6.219
Stage II Study 55 8.00 5.586
Refused 21 10.20 5.478
Control 40 3.20 4.005
Advanced Study 13 2.37 2.829
Stages Refused 18 1.86 3.716
N = no. of cases, Std Dev = standard deviation
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Table 5.5: Average and Standard Deviation of Total Years Lived after Detection
by Cancer Detection Stage – Continued
Stage and Survival DBC DOC
Group N Avg SD N Avg SD N Avg SD
Control 75 16.60 1.651 41 5.85 4.478 18 7.76 5.333
Combined Study 81 16.66 1.468 36 7.75 4.474 26 9.44 4.534
Stage I Refused 18 16.67 1.616 2 2.08 0.707 12 7.44 4.074
Control 21 16.68 1.362 68 4.10 3.796 5 5.77 3.481
Stage II Study 12 16.39 1.348 36 4.78 3.147 7 10.17 3.342
Refused 5 16.50 1.174 13 6.46 3.009 3 15.92 1.887
Control 1 17.92 . 38 2.61 2.995 1 11.17 .
Advanced Study 0 . . 12 1.69 1.446 1 10.58 .
Stages Refused 0 . . 18 1.86 3.716 0 . .
N = no. of cases, Avg = average, SD = standard deviation
DBC = death from breast cancer, DOC = death from other causes
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survived breast cancer are censored by end of follow-up. As for women who died
from breast cancer, women diagnosed at combined stage I in the study group have
a longer average of total years lived after detection than in the control group. The
refused group only has 2 observations and is therefore excluded from comparison.
For stage II detection, the averages of women who died from breast cancer are
similar in the control group and the study group, while the refused group seems
to have a higher average than the other groups. For advanced stage detection,
the study group and the refused group have a similar average, while the control
group has a higher average compare to the other groups.
Table 5.6 contains the average and standard deviation of total years lived after
birth, in years, for all cancer cases broken down by stage at detection. Table 5.7
contains the same information as in Table 5.6, only the information is broken
down further by outcomes at the end of HIP study.
No formal test is conducted to see if there is a significant difference in the
average of total years lived after birth among the control group, the study group
and the refused group. However, from inspection it can be seen that the study
and control groups have similar averages of total years lived after birth in all
stages of detection.
When the average of total years lived after birth is further broken down by
outcomes at the end of the HIP study, for combined stage I detection, the study
group always has either similar or longer average as compare with the other two
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Table 5.6: Average and Standard Deviation of Total Years Lived after Birth by
Cancer Detection Stage
Stage and All Cases
Group N Average Std Dev
Control 134 67.59 9.119
Combined Study 143 68.21 8.306
Stage I Refused 32 66.29 7.363
Control 94 61.42 8.068
Stage II Study 55 62.60 8.565
Refused 21 64.36 7.917
Control 40 58.24 7.574
Advanced Study 13 56.28 8.292
Stages Refused 18 57.08 6.077
N = no. of cases, Std Dev = standard deviation
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Table 5.7: Average and Standard Deviation of Total Years Lived after Birth by
Cancer Detection Stage – Continued
Stage and Survival DBC DOC
Group N Avg SD N Avg SD N Avg SD
Control 75 72.20 6.169 41 60.27 8.712 18 65.08 8.754
Combined Study 81 71.39 6.315 36 62.62 8.788 26 66.07 8.577
Stage I Refused 18 69.17 5.080 2 54.08 3.653 12 64.00 8.083
Control 21 69.91 6.887 68 58.50 6.462 5 65.47 5.778
Stage II Study 12 69.38 6.801 36 59.25 7.482 7 68.24 7.248
Refused 5 69.57 6.952 13 61.52 7.863 3 67.97 4.394
Control 1 66.33 . 38 57.62 7.192 1 73.83 .
Advanced Study 0 . . 12 55.04 7.293 1 71.17 .
Stages Refused 0 . . 18 57.08 6.077 0 . .
N = no. of cases, Avg = average, SD = standard deviation
DBC = death from breast cancer, DOC = death from other causes
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groups. While the refused group has the lowest average among the three groups
for combined stage I detection. For stage II detection, the average of the total
years lived since birth for women who survived breast cancer is similar in all three
groups.
All in all, we do not see many difference among the three groups in the averages




Analysis of Five-Year Survival Probability and
Normalized Data
Ideally, studies of the efficacy of screening should include information about the
curing probability of the breast cancer patients. Curing means that a patient has
completed the treatment and the doctor has declared that she is free of breast
cancer or her cancer is in remission. It will also be relevant to know the recurrence
probability of the breast cancer among women who were previously declared to
be free of cancer. However, the HIP study did not collect such information. In
the absence of such data, we will investigate the five-year survival probability
instead.
In this chapter we also will compare the un-normalized and normalized yearly
proportion of women who survived breast cancer, died from breast cancer and
died from other cause. By conducting this analysis, we hope to learn about the
conditional survival probability and breast cancer mortality.
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6.1 Five-year Survival Probability
The five-year survival probability is generally used as a measure to assess the
success of a cancer treatment. The five-year survival is measured from the time
of cancer diagnosis. Those women who survive five years can be in either a cancer
free state, or a therapy state or a recurrence state.
Some medical researchers argues that for the breast cancer, five years is not
long enough to follow the history of the disease. They proposed a ten years or
even fifteen years of follow-up. The HIP study had about 3.5 years of screening
(although the actual screening period was longer than that) and 15 years of follow-
up. Thus we have about 18 years of history of the breast cancer development. It
enables us to analyze a ten-year survival probability as well. We will also analyze
a shorter three-year survival probability for comparison purposes.
Table 6.1, Table 6.2 and Table 6.3 give a yearly account on how many women
survived breast cancer, died from breast cancer and died from other causes in
each of the three groups. These numbers are calculated based on the breast
cancer diagnosed date, not the entry date to the HIP study.
Yearly survival proportions for each possible outcome (survived the breast
cancer, died from breast cancer or died from other causes) are given in Figure 6.1,
Figure 6.2 and Figure 6.3. Each graph consists of three lines, one for each group.
The proportion is computed as the number of occurrences of a particular outcome
divided by the total number of cases.
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Table 6.1: Yearly Data of Women Survived Breast Cancer, Died From Breast
Cancer and Died from Other Causes among Cancer Cases in the Control Group
End of Survival Death from Death from Total
nth Year Breast Cancer Other Causes Cases
1 241 25 2 268
2 206 59 3 268
3 186 78 4 268
4 168 91 9 268
5 155 102 11 268
6 147 110 11 268
7 139 118 11 268
8 132 124 12 268
9 125 129 14 268
10 120 133 15 268
11 118 134 16 268
12 113 136 19 268
13 109 139 20 268
14 106 140 22 268
15 104 142 22 268
16 100 145 23 268
17 97 147 24 268
18 97 147 24 268
81
Table 6.2: Yearly Data of Women Survived Breast Cancer, Died from Breast
Cancer and Died from Other Causes among Cancer Cases in the Study Group
End of Survival Death from Death from Total
nth Year Breast Cancer Other Causes Cases
1 203 7 1 211
2 190 20 1 211
3 181 29 1 211
4 175 33 3 211
5 163 44 4 211
6 150 54 7 211
7 147 55 9 211
8 136 61 14 211
9 129 66 16 211
10 118 73 20 211
11 116 73 22 211
12 112 77 22 211
13 107 79 25 211
14 103 81 27 211
15 101 81 29 211
16 98 81 32 211
17 94 83 34 211
18 93 84 34 211
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Table 6.3: Yearly Data of Women Survived Breast Cancer, Died from Breast
Cancer and Died from Other Causes among Cancer Cases in the Refused Group
End of Survival Death from Death from Total
nth Year Breast Cancer Other Causes Cases
1 60 10 1 71
2 53 17 1 71
3 49 20 2 71
4 46 22 3 71
5 45 23 3 71
6 44 24 3 71
7 40 26 5 71
8 36 28 7 71
9 35 28 8 71
10 31 31 9 71
11 28 32 11 71
12 28 32 11 71
13 28 32 11 71
14 28 32 11 71
15 26 32 13 71
16 25 32 14 71
17 24 33 14 71
18 23 33 15 71
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Figure 6.1: Proportion of Survival
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Figure 6.2: Proportion of Death from Breast Cancer
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Figure 6.3: Proportion of Death from Other Causes
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Table 6.4: Proportions of Survival, Deaths from Breast Cancer and Death from
Other Causes Three Years after Diagnosis
Proportions of
Group Survival DBC DOC
Control 69.4% 29.1% 1.5%
Study 85.8% 13.7% 0.5%
Refused 69.0% 28.2% 2.8%
DBC = Deaths from Breast Cancer
DOC = Deaths from Other Causes
The graphs show that the survival proportion of the study group is always
higher than that of the control group. Also the proportion of deaths from breast
cancer in the study group is always lower than that of the control group.
As for the refused group, the graphs do not show a consistent pattern. Some-
times it is similar to the control group and some other times it is close to that of
the study group.
The survival proportions, deaths from breast cancer and deaths from other
causes of the three groups three years after diagnosis where given in Table 6.4.
While Table 6.5 and Table 6.6 contain similar information only for five and ten
years after diagnosis respectively.
It can be seen from Figure 6.1 that the largest survival proportion differ-
ence between the study group and the control group happens in the fourth and
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Table 6.5: Proportions of Survival, Deaths from Breast Cancer and Death from
Other Causes Five Years after Diagnosis
Proportions of
Group Survival DBC DOC
Control 57.8% 38.1% 4.1%
Study 77.3% 20.9% 1.9%
Refused 63.4% 32.4% 4.2%
DBC = Deaths from Breast Cancer
DOC = Deaths from Other Causes
Table 6.6: Proportions of Survival, Deaths from Breast Cancer and Death from
Other Causes Ten Years after Diagnosis
Proportions of
Group Survival DBC DOC
Control 44.8% 49.6% 5.6%
Study 55.9% 34.6% 9.5%
Refused 43.7% 43.7% 12.7%
DBC = Deaths from Breast Cancer
DOC = Deaths from Other Causes
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fifth year after diagnosed. After the fifth year, the difference decreases as time
increases.
It is also interesting to note that the proportion of deaths from other causes
in the study group and the refused group increases at a faster rate over time than
that in the control group. As discussed in Chapter 3, this probably happened
because more women survived breast cancer in the study group but then they
died from other causes. Unfortunately, the HIP study has no specific record of
the causes of death other than the breast cancer. If it had, it would have been
possible to ascertain whether or not the other causes of death somehow is related
to breast cancer.
We should however point out that the above is only an informal discussion. We
have not carried out any formal statistical analysis such as variance calculation
or hypothesis testing.
6.2 Normalized Data–Conditional Probabilities
Our next task is to compare changes in these proportions when the data are
normalized for third, fifth and tenth year after detection. By normalizing, we
mean using the number of survival of a particular year as the starting number
and use this number as the denominator to compute the normalized proportion
of three outcomes annually in the subsequent years. In other words, we are
estimating the conditional probabilities of survival, death from breast cancer and
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Figure 6.4: Proportion of Survival - Normalized for Year 3
death from other causes, given that a patient has survived a specified number of
years, say five. The fifth-year normalized data for the control group, the study
group and the refused group are given in Table 6.7, Table 6.8 and Table 6.9.
The graphs for the third year normalized proportion of each outcome are
given in Figure 6.4, Figure 6.5 and Figure 6.6, for the fifth year are given in Fig-
ure 6.7, Figure 6.8 and Figure 6.9, and for the tenth year are given in Figure 6.10,
Figure 6.11 and Figure 6.12.
In the first few years, third-year normalized survival proportions for the study
group are higher than those of the control group before both proportions actually
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Table 6.7: Fifth Year Normalized Data of Women Survived Breast Cancer, Died
from Breast Cancer and Died from Other Causes in the Control Group
End of Survival Death from Death from Total
nth Year Breast Cancer Other Causes Cases
1 . . . .
2 . . . .
3 . . . .
4 . . . .
5 155 0 0 155
6 147 8 0 155
7 139 16 0 155
8 132 22 1 155
9 125 27 3 155
10 120 31 4 155
11 118 32 5 155
12 113 34 8 155
13 109 37 9 155
14 106 38 11 155
15 104 40 11 155
16 100 43 12 155
17 97 45 13 155
18 97 45 13 155
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Table 6.8: Fifth Year Normalized Data of Women Survived Breast Cancer, Died
from Breast Cancer and Died from Other Causes in the Study Group
End of Survival Death from Death from Total
nth Year Breast Cancer Other Causes Cases
1 . . . .
2 . . . .
3 . . . .
4 . . . .
5 163 0 0 163
6 150 10 3 163
7 147 11 5 163
8 136 17 10 163
9 129 22 12 163
10 118 29 16 163
11 116 29 18 163
12 112 33 18 163
13 107 35 21 163
14 103 37 23 163
15 101 37 25 163
16 98 37 28 163
17 94 39 30 163
18 93 40 30 163
92
Table 6.9: Fifth Year Normalized Data of Women Survived Breast Cancer, Died
from Breast Cancer and Died from Other Causes in the Refused Group
End of Survival Death from Death from Total
nth Year Breast Cancer Other Causes Cases
1 . . . .
2 . . . .
3 . . . .
4 . . . .
5 45 0 0 45
6 44 1 0 45
7 40 3 2 45
8 36 5 4 45
9 35 5 5 45
10 31 8 6 45
11 28 9 8 45
12 28 9 8 45
13 28 9 8 45
14 28 9 8 45
15 26 9 10 45
16 25 9 11 45
17 24 10 11 45
18 23 10 12 45
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Figure 6.5: Proportion of Death from Breast Cancer - Normalized for Year 3
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Figure 6.6: Proportion of Death from Other Causes - Normalized for Year 3
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Figure 6.7: Proportion of Survival - Normalized for Year 5
converge. While the third-year normalized death from breast cancer proportions
for the control group are higher than the study group. The third-year normalized
death from other causes proportions in the study group are still higher than those
of the control group although it seems that the differences are more pronounce
compare to the un-normalized proportions.
For the fifth-year normalized survival proportion, there are several interesting
facts. The fifth-year normalized survival curve of the control group actually is
not better than that of the study group. Also, the cancer mortality curve of
the control group is only slightly higher than those of the study group. However,
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Figure 6.8: Proportion of Death from Breast Cancer - Normalized for Year 5
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Figure 6.9: Proportion of Death from Other Causes - Normalized for Year 5
98
normalized curve of the death from other causes of the study group is much higher
than that of the control group. Two conclusions can be drawn here. First, even
though the fifth-year normalized survival proportions of the study group are not
better than those of the control group, it does not mean that screening is not
beneficial, since the fifth-year normalized proportion of deaths from other causes
of the study group is still much higher than that of the control group. Second, if
the breast cancer was not cured (or in remission) after five years, than it probably
was either a deadly cancer or detected in an advanced stage for which screening
offers no benefit and thus the fifth-year normalized curve of deaths from breast
cancer are expected to be similar in the control group and the study group.
The tenth-year normalized proportions behave similarly to the fifth-year nor-
malized proportions. The similarity is more pronounced as expected, since the
effect of screening wear out as time goes on.
It will be interesting to conduct a refined study of the fifth-year and the
tenth-year normalized data by detection stages.
The fifth-year normalized proportion of cancer by detection stage is given in
Table 6.10. Comparing Table 6.10 to Table 5.1, that is subtracting number of
cases for the fifth-year normalized data (Table 6.10) from number of cases for the
un-normalized data (Table 5.1), gives the number of women died in the first five
years after detection. Because there are only few observations beyond stage II,
we shall only analyze data involving stage I and stage II detection. Table 6.11
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Figure 6.10: Proportion of Survival - Normalized for Year 10
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Figure 6.11: Proportion of Death from Breast Cancer - Normalized for Year 10
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Figure 6.12: Proportion of Death from Other Causes - Normalized for Year 10
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Table 6.10: Breast Cancer by Detection Stage - Normalized for Year 5
Control Study Refused
Stage N % N % N %
Stage I 93 60.00% 121 74.23% 23 51.11%
Stage II 42 27.10% 33 20.25% 17 37.78%
Stage III 8 5.16% 1 0.61% 1 2.22%
Stage IV 0 0.00% 0 0.00% 0 0.00%
Clinical Stage I or II 12 7.74% 8 4.91% 4 8.88%
Unknown 0 0.00% 0 0.00% 0 0.00%
Total 155 163 45
N = no. of cases, % = percentage
contains the number of women died either from breast cancer or from other causes
in the first five years after detection. The percentage was calculated with respect
to number of cases of the un-normalized data.
From Table 6.11, we know that for stage I detection of the control group there
is a total of 27 deaths in the first 5 years after detection, 20 of them or 16.67% of
cancer cases in control group died from breast cancer. While for stage I detection
of the study group for the same period of time, there is a total of 14 deaths, 10
of them or 7.41% died from breast cancer. Thus the proportion of cancer death
in the control group is more than twice than the study group. However, for stage
II detection, there is 52.13% of cancer death in the control group as opposed to
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Table 6.11: Number of Death during the First Five Years after Diagnosis
Stage Breast Cancer Other Causes
and No of Death Death Death
Group Cases N % N % N %
Control 120 27 22.50% 20 16.67% 7 5.83%
Stage I Study 135 14 10.37% 10 7.41% 4 2.96%
Refused 28 5 17.86% 2 7.14% 3 10.71%
Control 94 52 55.32% 49 52.13% 3 3.19%
Stage II Study 55 22 40.00% 22 40.00% 0 0.00%
Refused 21 4 19.05% 4 19.05% 0 0.00%
N = no. of cases, % = percentage
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40.00% in the study group. Thus the difference between two groups is not much.
Here we can conclude that women will not benefit from screening if the breast
cancer is detected in a later stage.
The tenth-year normalized proportion of cancer by detection stage is given
in Table 6.12. Comparing Table 6.12 to Table 6.10 in the same way as before
gives the number of women died in the second five years after detection. Again
because of only few observations beyond stage II detection, the comparison is only
conducted for stage I and stage II detection. Table 6.13 contains the number of
women died either from breast cancer or from other causes in the second five
years after detection. The proportion is taken by using the number of cases as
the denominator as in Table 6.11.
From Table 6.13, during the second five years after detection for stage I detec-
tion in the control group, there are 11 women or 9.17% died from breast cancer.
While in the study group, 17 women or 12.59% died from breast cancer. How-
ever for stage II detection, 14 women or 14.89% died from breast cancer in the
control group and 12 women or 21.82% died from cancer. Here we have more
breast cancer deaths in the study group. One plausible explanation for this phe-
nomenon is that there is some kind of death delay effect in the study group;
that is, some women who survived the first five years might not have been re-
ally cured. Instead the treatment they received only prolonged their life without
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Table 6.12: Breast Cancer by Detection Stage - Normalized for Year 10
Control Study Refused
Stage N % N % N %
Stage I 80 66.67% 96 81.36% 17 54.84%
Stage II 27 22.50% 17 14.41% 9 29.03%
Stage III 4 3.33% 1 0.85% 1 3.23%
Stage IV 0 0.00% 0 0.00% 0 0.00%
Clinical Stage I or II 9 7.50% 4 3.39% 4 12.90%
Unknown 0 0.00% 0 0.00% 0 0.00%
Total 120 118 31
N = no. of cases, % = percentage
106
Table 6.13: Number of Death during the Second Five Years after Diagnosis
Stage Breast Cancer Other Causes
and No of Death Death Death
Group Cases N % N % N %
Control 120 13 10.83% 11 9.17% 2 1.67%
Stage I Study 135 25 18.52% 17 12.59% 8 5.93%
Refused 28 6 21.43% 0 0.00% 6 21.43%
Control 94 15 15.96% 14 14.89% 1 1.06%
Stage II Study 55 16 29.09% 12 21.82% 4 7.27%
Refused 21 8 38.10% 8 38.10% 0 0.00%
N = no. of cases, % percentage
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actually curing them. Another plausible explanation is that these might be a




Suppose there is no screening, then breast cancer will be detected, say at age V .
With screening and assuming it is beneficial, the breast cancer will be detected at
an earlier age, say Y . We shall call V the actual detection time. Some researchers,
for example Shapiro et al (1982) and Xu et al (1995), called the difference V −Y
the lead time. The lead time, if it exists, is a relevant factor in assessing the
efficacy of screening. In comparing the survival times of cancer patients in the
study and the control groups, the lead time should be removed first. Otherwise,
the possible longer survival times for the study group may be just an artificial
effect and can be attributed to the lead time. Note the the lead time so defined
is not an observable quantity, since V does not exist for a woman whose breast
cancer was screening detected. Several stochastic models have been proposed in
the literature to analyze the lead time effect. See, for example Xu et al (1995)
and Xu et al (1999).
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Table 7.1: Average and Standard Deviation of Detection Age
Group N Average Std Dev
Control 268 54.578 6.6065
Study 211 54.483 6.5533
Refused 71 53.915 6.0018
Std Dev = standard deviation
Our approach to studying the lead time is to compare the distributions of the
age at detection of breast cancer among the three groups.
First, ANOVA is conducted to test whether the means of detection age among
groups are significantly different. The average and standard deviation of detection
age for each group are given in Table 7.1. ANOVA shows no significant difference
in the means (the F statistic is 0.29 with 2 degree of freedom which produces a
p-value of 0.7456).
Next, we examine the binned data (according to age groups) of the age distri-
bution at detection as given in Table 7.2. The test of equality of three multinomial
distributions also showed no significant difference among the three groups. The
chi-square statistic from this test is 7.2993 with 8 degree of freedom which gives
a p-value of 0.5047.
Our final analysis is to use a ”shift model” to investigate the lead time. Let Y
be the age of detection of a cancer patient in the study group and X be the age
of detection of a cancer patient in the control group. Set the expected lead time
110
Table 7.2: Table of Detection Age Group
Control Study Refused
Detection Age Group N % N % N %
Detection age ≤ 45 26 9.70% 21 9.95% 5 7.04%
46 ≤ detection age ≤ 50 60 22.39% 44 20.85% 20 28.17%
51 ≤ detection age ≤ 55 56 20.90% 50 23.70% 14 19.72%
56 ≤ detection age ≤ 60 62 23.13% 57 27.01% 22 30.99%
Detection age ≥ 61 64 23.88% 39 18.48% 10 14.08%
Total 268 211 71
N = no of cases, % = percentage
E(X − Y ) = θ. We suppose that X = Y + θ. Then the distribution function of
X is F (x− θ) where F is the distribution function of Y . If the lead time indeed
exists, then θ > 0.
The empirical distribution functions for detection age (measured in years)
for the control group, the study group and the refused group are given in Fig-
ure 7.1. The three empirical distribution functions are very close to one another.
A estimate of lead time θ would be practically zero.
In summary, in all the statistical analysis that we conducted, we found no
compelling evidence of the existence of significant lead time.
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For future work, we would like to propose a Markov chain model to compare the
study group and the control group. In our opinion, an appropriate Markov chain
would take into account a multitude of transition patterns of the breast patients
over the course of the disease development. We had made such an attempt but
quickly realized that it was impossible to use Markov chain to analyze the the
HIP data, because the HIP data did not record the dates of patients’ remission
and recurrences. Such information is needed for Markov chain analysis.
Nevertheless, we will present in this chapter such a Markov chain model and
hopefully there will be more suitable data for analysis in the future. The Markov
chain model that we propose is a four-state Markov chain. We construct one
four-state Markov chain to model the transitions of each individual in the study
group. Another four-state Markov chain will be used to model transitions of each
individual in the control group and refused group.
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For the study group, the four states are labelled by {0, 1, 2, 3}, where 0 is
the disease free (or healthy) state, 1 is the pre-clinical disease state where an
individual unknowingly has disease which can be detected by screening, 2 is the
death state due to causes unrelated to breast cancer, and 3 is the death state
caused by breast cancer.
For the control group, the four states are labelled by {0, 1, 2, 3}, where 0 is
the disease free state, 1 is the clinical disease state where the cancer is detected
without screening, 2 is the death state due to causes unrelated to breast cancer
and 3 is the death state caused by breast cancer.
Individuals in the refused group follow a similar Markov chain as those in the
control group.
It is obvious that states 2 and 3 are the absorbing states, while an individual
can make transition from state 0 → 1 → 0 → 1 and so on before finally enters
state 2 or 3.
A simple Markov chain may be constructed as follows. Assume that an indi-
vidual with breast cancer is always diagnosed before death (an individual cannot
go from state 0 to state 3 directly). Furthermore, for simplicity assume that an
individual will not die from causes other than breast cancer (an individual cannot
go from state 1 to state 2). The diagrams of the states are as follow
2← 0↔ 1→ 3
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We can generalized this model to include breast cancer cases that are not
diagnosed before death and also the possibility that individuals can die from
other causes.
If screening is advantageous, then the time to pre-clinical detection will be
shorter than time to clinical detection. That is the sojourn time from state 0→ 1
in the study group will be shorter than the sojourn time from state 0→ 1 in the
control group. Consequently the curing rate, which defined as the transition rate
from state 1 → 0 in both the study group and the control group, will be bigger




Assessing the efficacy of screening for the breast cancer is indeed not an easy
task. There are problems in every level of investigation, starting from the data
collection up to the data analysis.
The most common study design used in this type of investigation is a random-
ized control trial. One argument that is often raised is how random is random.
In the HIP project, at the beginning of the study there are twice as many women
excluded from the project in the study group compared to the control group.
This fact often raises question about bias in including/excluding women from
the project. Aside from the bias in including/excluding women issue, one major
problem in HIP is the compliance of the women in the project. In the data anal-
ysis, the major problem is selecting the start point and end point for the purpose
of comparing the study group and the control group and treatment of the death
due to other causes.
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The HIP project does have its own advantages, because it is possibly one of
the largest randomized controlled trial that was conducted when breast cancer
screening is not as popular as it is now. One problem in recent breast cancer
screening studies is that women in the control group are more likely conducting
their own independent breast examination. In some studies, they are even told
to conduct self-examination.
The key to better breast cancer survival seems to lie in early detection of
the cancer. During the screening period, there are 0.877% breast cancer cases
detected in the control group as oppose to 1.047% cases in the study group, a
0.17% difference. This difference in proportions is not statistically significant.
Further investigation shows that the study group had a significantly higher stage
I detection compare to the control group (50.00% in the control group as opposed
to 67.77% in the study group). Analysis also shows that the study group has a
better survival probability and also a lower death from breast cancer proportion
compared to the control group. This proves that screening results in a higher
early stage detection proportion in study group which in turn leads to better
survival and less breast cancer death.
Because of these reasons, we conclude that breast cancer screening is beneficial
for women. However, we would also remark that breast cancer screening in the
HIP study consists of both mammography and examination by surgeons. Our
conclusion does not imply that mammography alone is also advantageous.
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